ACADIA Pharmaceuticals Inc. (ACAD)
NASDAQ: ACAD · Real-Time Price · USD
22.67
+0.37 (1.66%)
At close: Apr 28, 2026, 4:00 PM EDT
22.60
-0.07 (-0.31%)
After-hours: Apr 28, 2026, 5:09 PM EDT
ACADIA Pharmaceuticals Stock Forecast
Stock Price Forecast
The 22 analysts with 12-month price forecasts for ACADIA Pharmaceuticals stock have an average target of 30.55, with a low estimate of 17 and a high estimate of 40. The average target predicts an increase of 34.76% from the current stock price of 22.67.
Analyst Consensus: Buy
* Price targets were last updated on Mar 25, 2026.
Analyst Ratings
The average analyst rating for ACADIA Pharmaceuticals stock from 22 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 7 | 7 | 7 | 8 | 8 |
| Buy | 8 | 8 | 8 | 10 | 9 | 9 |
| Hold | 6 | 7 | 6 | 5 | 4 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 21 | 23 | 22 | 23 | 22 | 22 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| B of A Securities | B of A Securities | Hold → Strong Buy Upgrades $29 | Hold → Strong Buy | Upgrades | $29 | +27.92% | Mar 25, 2026 |
| JP Morgan | JP Morgan | Buy Maintains $31 → $34 | Buy | Maintains | $31 → $34 | +49.98% | Mar 4, 2026 |
| TD Cowen | TD Cowen | Strong Buy Maintains $35 → $37 | Strong Buy | Maintains | $35 → $37 | +63.21% | Feb 26, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $31 → $30 | Buy | Maintains | $31 → $30 | +32.33% | Feb 26, 2026 |
| Citizens | Citizens | Buy Maintains $34 → $35 | Buy | Maintains | $34 → $35 | +54.39% | Feb 26, 2026 |
Financial Forecast
Revenue This Year
1.27B
from 1.07B
Increased by 18.80%
Revenue Next Year
1.42B
from 1.27B
Increased by 11.70%
EPS This Year
0.50
from 2.30
Decreased by -78.41%
EPS Next Year
1.00
from 0.50
Increased by 100.59%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 1.3B | 1.5B | ||||||
| Avg | 1.3B | 1.4B | ||||||
| Low | 1.2B | 1.2B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 24.2% | 20.9% | ||||||
| Avg | 18.8% | 11.7% | ||||||
| Low | 11.9% | -3.1% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 1.12 | 2.04 | ||||||
| Avg | 0.50 | 1.00 | ||||||
| Low | 0.20 | 0.01 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -51.2% | 310.2% | ||||||
| Avg | -78.4% | 100.6% | ||||||
| Low | -91.5% | -98.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.